Europe Cervical Cancer Tests Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

19/feb/2018 11:25:26 pbi Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Europe Cervical Cancer Test Market: Cervical cancer is the disease caused by abnormal growth of the cervical cells in the cervix. Cervical cancer is most commonly occurs in women owing to genital Human Papilloma Virus (HPV) infection. It is the most common type of cancer in women and the symptoms in early stages are very low, however, the vaginal bleeding after menopause and pelvic pain are the symptoms shown in a later stage. Cervical cancer can be diagnosed by HPV testing, Pap smear testing, and colposcopy among others.

 Europe Cervical Cancer Test Market: 

 Increase in the prevalence of cervical cancer in Europe region, growing the geriatric female population, and rise in awareness about the cervical cancer screening methods are anticipated to fuel the Europe cervical cancer test market. Furthermore, initiatives were taken by the government and various organizations for the prevention and control of cervical cancer, increase in incidence rate of HPV infections, and launching of low-cost Visual Inspection with Acetic acid (VIA) tests are driving the Europe cervical cancer test market. However, stringent regulatory guidelines, lack of early-stage symptoms, lack of reimbursement policies for disease diagnosis, and underdeveloped healthcare infrastructure are the factors restraining the Europe Cervical Cancer Test Market.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/europe-cervical-cancer-tests-market/#ulp-4H8Z4LpNMLEuOnnx 

 

 

 

Europe cervical cancer test market is segmented on the basis of test type and end user

 

Based on the test type, Europe cervical cancer test market is segmented into the following:

·         Colposcopy

·         Pap smear tests

·         Endo-cervical curettage

·         Human Papilloma Virus (HPV) testing

·         Visual Inspection with Acetic acid (VIA) testing

·         Others

 

Based on the end user, Europe cervical cancer test market is segmented into the following:

·         Hospitals

·         Oncology centres

·         Diagnostic centres

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/europe-cervical-cancer-tests-market/#ulp-c654SbFYO64MsOhu

 

 

Europe cervical cancer test market is growing at a significant CAGR owing to technological advancements in cervical cancer diagnostic equipment and procedures. Moreover, unsafe sex with HPV-positive patients, lifestyle changes such as smoking, and obesity are also anticipated to upsurge the revenue of Europe cervical cancer test market over the forecast period. However, increase in the prevalence of cervical cancer in Europe region expected to drive the Europe cervical cancer test market. For instance, according to International Agency for Research on Cancer 2012, the incidence rate of cervical cancer is 13.4 per 100,000 people and mortality rate is 4.9 per 100,000 people. However, mortality is decreasing owing to increase in the technological advancements of disease diagnostics and launching of low-cost test such as Visual Inspection with Acetic acid (VIA) test. Moreover, acquisitions and mergers and diversification of business segments are the strategies followed by the market players to increase their revenue in Europe cervical cancer test market. For instance, in July 2011, Roche has acquired mtm laboratories AG for the expansion of cervical cancer testing market in the Europe region.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/europe-cervical-cancer-tests-market/#ulp-14mlyhjMGhVjZqa3

 

 

 

According to World Health Organization Europe, approximately 28,000 women die from cervical cancer every year in the Europe region. The prevalence rate is higher in Germany, France, and U.K. (according to cancer research UK 2014, about 3,224 new cervical cancer cases were diagnosed in the U.K.). Due to change in lifestyles such as smoking, unsafe sex, and high adoption of technological advanced diagnostic tests are anticipated to fuel the Europe cervical cancer test market. Moreover, government initiations for creating awareness about the cervical cancer diagnostic tests and increase in R&D investment for the innovation of novel technologies also expected to propel the Europe cervical cancer test market over the forecast period.

 

 

Some of the players in Europe cervical cancer test market are F. Hoffmann La Roche Ltd. (Switzerland), Abbott Diagnostics (U.S.), Oncognostics GmbH (Germany), Becton, Dickinson and company (U.S.), Randox Laboratories Ltd. (U.K.), Epigenomics AG (Germany), Beckman Coulter (U.S.), and Fujirebio Diagnostics, Inc. (U.S.) to name a few.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/europe-cervical-cancer-tests-market/

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl